cervical cancer
Conditions
Interventions
Single arm:anlotinib
Sponsors
Guangxi Medical University Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: ? The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up; ? Female, age = 18 years old (calculated on the date of signing the informed consent form); ? Patients with low and middle differentiated cervical squamous cell carcinoma diagnosed by pathology; ? It contains one of the following high-risk factors: positive lymph nodes; Positive incisional margin; Vascular tumor thrombus; The tumor did not reach CR after standardized concurrent radiotherapy and chemotherapy (imaging, gynecological examination and tumor marker SCC were not normal); ? Or cervical adenocarcinoma diagnosed by pathology and special types such as neuroendocrine small cell carcinoma and mixed tumor; ? ECoG score: 0-1; ? The functions of important organs meet the following requirements (it is not allowed to use any blood components within the first 14 days of randomization): ? absolute neutrophil count = 1.5x10^9/l; ? platelet = 80x10^9/l; ? hemoglobin = 9g/dl; ? bilirubin = 1.5 times ULN ? alt, AST = 3 times ULN ? serum creatinine = 1.5 times ULN
Exclusion criteria
Exclusion criteria: ? Those who are unable to swallow the tablets normally, or have abnormal gastrointestinal function, which may affect the drug absorption according to the judgment of the researcher. ? Patients with hypertension who cannot be well controlled by antihypertensive drugs (systolic blood pressure = 140mmHg or diastolic blood pressure = 90mmHg). ? Abnormal coagulation function, or known hereditary or acquired bleeding tendency and thrombotic tendency; ? Distant metastasis; ? Pregnant or lactating women; ? Patients who have a history of psychotropic substance abuse and can not quit or have mental disorders; ? Patients who have participated in clinical trials of other drugs within 4 weeks; ? Those who have received VEGFR inhibitor treatment, such as apatinib, sorafenib and sunitinib; ? Severe allergic disease, history of severe drug allergy, and allergy to any component in the prescription of arotinib hydrochloride capsules; ? The investigator judges other situations that may affect the clinical research and the judgment of research results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-freesurvival time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Progression free survival time;Safety and tolerability;Overall Survival time; | — |
Countries
China
Contacts
Public ContactHonglin Song
Guangxi Medical University Cancer Hospital
Outcome results
None listed